BRAF v600e突变晚期非小细胞肺癌患者的小细胞转化

IF 0.6 Q3 MEDICINE, GENERAL & INTERNAL

BMJ Case Reports Pub Date : 2025-03-26 DOI:10.1136/bcr-2024-262278

Thanakorn Charoenthanadhol, Nipon Chaisuriya, Siraphong Putraveephong

{"title":"BRAF v600e突变晚期非小细胞肺癌患者的小细胞转化","authors":"Thanakorn Charoenthanadhol, Nipon Chaisuriya, Siraphong Putraveephong","doi":"10.1136/bcr-2024-262278","DOIUrl":null,"url":null,"abstract":"Non-small cell lung cancer (NSCLC) with a BRAF V600E mutation is rare and associated with a worse prognosis compared with wild-type BRAF. The first-line treatment options include a combination of a BRAF inhibitor and a MEK inhibitor or immunotherapy with or without chemotherapy. Unlike advanced NSCLC with common EGFR mutations or ALK rearrangements, the mechanisms of resistance are poorly understood. We report a case of small cell transformation after treatment with a BRAF inhibitor and a MEK inhibitor, which illustrates one potential resistance mechanism. We extrapolated therapeutic data from de novo small cell lung cancer to this case. However, the outcome was unsatisfactory.","PeriodicalId":9080,"journal":{"name":"BMJ Case Reports","volume":"18 3","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Small cell transformation in a patient with BRAF V600E-mutated advanced non-small cell lung cancer.\",\"authors\":\"Thanakorn Charoenthanadhol, Nipon Chaisuriya, Siraphong Putraveephong\",\"doi\":\"10.1136/bcr-2024-262278\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Non-small cell lung cancer (NSCLC) with a BRAF V600E mutation is rare and associated with a worse prognosis compared with wild-type BRAF. The first-line treatment options include a combination of a BRAF inhibitor and a MEK inhibitor or immunotherapy with or without chemotherapy. Unlike advanced NSCLC with common EGFR mutations or ALK rearrangements, the mechanisms of resistance are poorly understood. We report a case of small cell transformation after treatment with a BRAF inhibitor and a MEK inhibitor, which illustrates one potential resistance mechanism. We extrapolated therapeutic data from de novo small cell lung cancer to this case. However, the outcome was unsatisfactory.\",\"PeriodicalId\":9080,\"journal\":{\"name\":\"BMJ Case Reports\",\"volume\":\"18 3\",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bcr-2024-262278\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bcr-2024-262278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

BRAF V600E突变的非小细胞肺癌（NSCLC）非常罕见，与野生型BRAF相比，其预后更差。一线治疗方案包括BRAF抑制剂和MEK抑制剂的联合治疗，或结合或不结合化疗的免疫治疗。与常见EGFR突变或ALK重排的晚期NSCLC不同，耐药机制尚不清楚。我们报告了一例BRAF抑制剂和MEK抑制剂治疗后的小细胞转化，这说明了一种潜在的耐药机制。我们将新发小细胞肺癌的治疗数据外推到本病例中。然而，结果并不令人满意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Small cell transformation in a patient with BRAF V600E-mutated advanced non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) with a BRAF V600E mutation is rare and associated with a worse prognosis compared with wild-type BRAF. The first-line treatment options include a combination of a BRAF inhibitor and a MEK inhibitor or immunotherapy with or without chemotherapy. Unlike advanced NSCLC with common EGFR mutations or ALK rearrangements, the mechanisms of resistance are poorly understood. We report a case of small cell transformation after treatment with a BRAF inhibitor and a MEK inhibitor, which illustrates one potential resistance mechanism. We extrapolated therapeutic data from de novo small cell lung cancer to this case. However, the outcome was unsatisfactory.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

BMJ Case Reports Medicine-Medicine (all)

CiteScore

1.40

自引率

0.00%

发文量

1588

期刊介绍： BMJ Case Reports is an important educational resource offering a high volume of cases in all disciplines so that healthcare professionals, researchers and others can easily find clinically important information on common and rare conditions. All articles are peer reviewed and copy edited before publication. BMJ Case Reports is not an edition or supplement of the BMJ.